Quoin Pharmaceuticals Ltd (QNRX) News

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial Results

Quoin Initiates Peeling Skin Syndrome Clinical Program Further Expansion of International Reach for Netherton...

Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient

Clinical Assessment Is Being Performed on a Pediatric Patient at Children’s Health Ireland in Dublin First...

Form 8-K - Current report

Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024

ASHBURN, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or...

Form DEF 14A - Other definitive proxy statements

Form ARS - Annual Report to Security Holders

Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome

Two Additional Clinical Sites to be Opened in the United Kingdom Both Sites are Recognized Centers of...

Form PRE 14A - Other preliminary proxy statements

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

ASHBURN, Va., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage...

Form 4 - Statement of changes in beneficial ownership of securities